Clinical significance of antibody against hepatitis B virus core antigen in patients with hepatitis C virus-related hepatocellular carcinoma

Liver International

Volumn 23, Issue 4, 2003, Pages 227-231

  Yano, Yoichi ^a   Yamashita, Fumihiko ^a   Sumie, Shuji ^a   Kuwaki, Kotaro ^a   Yamamoto, Hiroshi ^a   Toyoda, Naoko ^b   Ando, Eiji ^b   Tanaka, Masatoshi ^b   Sata, Michio ^b  

^a Saga Social Insurance Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibody to hepatitis B core antigen (anti HBc); Hepatitis C virus (HCV); Hepato cellular carcinoma (HCC); Prognosis

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; SERUM ALBUMIN; VIRUS DNA;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PORTAL VEIN THROMBOSIS; SEROLOGY; SURVIVAL RATE; TUMOR VOLUME;

EID: 0142093018     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.00831.x     Document Type: Article

References (20)

1. Okuda K, Fujimoto I, Hanai A, et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
2. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B infection in subjects without hepatitis B surface antigen: clinically significant or purely "Occult"? Hepatology 2001; 34: 194-203.
3. Torbenson M, Thomas D L. Occult hepatitis B. Lancet 2002; 2: 479-86.
4. Joller-Jemelka H I, Wicki A N, Grob P J. Detection of HBs antigen in 'anti-HBc alone' positive sera. J Hepatol 1994; 21: 269-72.
5. Dickson R C, Everhart J E, Lake J R, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 1668-74.
6. Marusawa H, Umemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-95.
7. Sheu J C, Huang G T, Shih L N, et al. Hepatitis C and B viruses in hepatitis surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103: 1322-27.
8. Paterlini P, Driss F, Nalpas B, et al. Persistence of hepatitis Band hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993; 17: 20-29.
9. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31: 552-8.
10. Okada S, Sato T, Okusaka T, et al. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer 1998; 77: 2028-31.
11. Marusawa H, Osaki Y, Kimura T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999; 45: 284-8.
12. Ide T, Kumashro R, Koga Y, et al. A real-time quantitative polymerase chain reaction for hepatitis B virus in patients with chronic hepatitis B treated with lamivudime. Am J Gastroenterol, (in press).
13. Shiratori Y, Shiina S, Zhang P Y, et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997; 80: 2060-7.
14. Yamanaka N, Takada M, Tanaka T, et al. Viral serostatus and coexisting inflammatory activity affect metachronous carcinogenesis after hepatectomy for hepatocellular carcinoma. A further report. J Gastroenterol 2000; 35: 206-13.
15. Kubo S, Nishiguchi S, Hirosaki K, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86: 793-8.
16. Alexopoulos C G, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999; 81: 69-74.
17. Liaw Y F, Sheen I S, Chen T G, et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991; 13: 627-31.
18. Huo T I, Wu J C, Lee P C, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28: 231-6.
19. Child C G, Turcotte J G. Surgery and portal hypertension. In: Child C G., ed The Liver and Portal Hypertension. Philadelphia: WB Saunders, 1964; 49-51.
20. Hermanek P, Sobin L H, (eds), TNM Classification of Malignant Tumors, 4th edn. Berlin: UICC, 1987.